Daesung Microbiological Labs. Co. Ltd Asset Resilience Ratio
Daesung Microbiological Labs. Co. Ltd asset resilience ratio. Daesung Microbiological Labs. Co. Ltd (036480) has an Asset Resilience Ratio of 10.25% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 036480 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Daesung Microbiological Labs. Co. Ltd (2012–2025)
Asset resilience ratio of Daesung Microbiological Labs. Co. Ltd from 2012 to 2025. This chart shows how Daesung Microbiological Labs. Co. Ltd's Asset Resilience Ratio has changed over time. Read 036480 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Daesung Microbiological Labs. Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Daesung Microbiological Labs. Co. Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩5.94 Billion | 10.25% |
| Total Liquid Assets | ₩5.94 Billion | 10.25% |
Asset Resilience Insights
- Moderate Liquidity: Daesung Microbiological Labs. Co. Ltd has 10.25% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Daesung Microbiological Labs. Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Daesung Microbiological Labs. Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Daesung Microbiological Labs. Co. Ltd Asset Resilience Ratio by Year (2012–2025)
Daesung Microbiological Labs. Co. Ltd asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Daesung Microbiological Labs. Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.25% | ₩5.94 Billion ≈ $4.03 Million |
₩57.98 Billion ≈ $39.29 Million |
-5.26pp |
| 2024-12-31 | 15.51% | ₩9.05 Billion ≈ $6.14 Million |
₩58.38 Billion ≈ $39.56 Million |
-2.73pp |
| 2023-12-31 | 18.24% | ₩11.73 Billion ≈ $7.95 Million |
₩64.29 Billion ≈ $43.57 Million |
-1.51pp |
| 2022-12-31 | 19.75% | ₩12.86 Billion ≈ $8.71 Million |
₩65.11 Billion ≈ $44.12 Million |
+3.88pp |
| 2021-12-31 | 15.86% | ₩9.93 Billion ≈ $6.73 Million |
₩62.62 Billion ≈ $42.44 Million |
-0.28pp |
| 2020-12-31 | 16.14% | ₩10.05 Billion ≈ $6.81 Million |
₩62.26 Billion ≈ $42.19 Million |
-8.49pp |
| 2019-12-31 | 24.63% | ₩12.50 Billion ≈ $8.47 Million |
₩50.77 Billion ≈ $34.40 Million |
-4.70pp |
| 2018-12-31 | 29.33% | ₩11.17 Billion ≈ $7.57 Million |
₩38.10 Billion ≈ $25.82 Million |
+2.98pp |
| 2017-12-31 | 26.35% | ₩9.17 Billion ≈ $6.21 Million |
₩34.78 Billion ≈ $23.57 Million |
-1.44pp |
| 2016-12-31 | 27.79% | ₩9.90 Billion ≈ $6.71 Million |
₩35.61 Billion ≈ $24.13 Million |
+22.98pp |
| 2015-12-31 | 4.82% | ₩1.56 Billion ≈ $1.06 Million |
₩32.42 Billion ≈ $21.97 Million |
+1.02pp |
| 2014-12-31 | 3.79% | ₩1.05 Billion ≈ $714.28K |
₩27.79 Billion ≈ $18.83 Million |
+0.37pp |
| 2013-12-31 | 3.42% | ₩990.00 Million ≈ $670.91K |
₩28.95 Billion ≈ $19.62 Million |
-0.74pp |
| 2012-12-31 | 4.16% | ₩1.06 Billion ≈ $719.02K |
₩25.49 Billion ≈ $17.28 Million |
-- |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more